E-mail

E-mail a Wiley Online Library Link

James P. Stevenson, Corey J. Langer, Robert A. Somer, Tracey L. Evans, Kumar Rajagopalan, Kimberly Krieger, Mona Jacobs-Small, Nikolas Dyanick, Barry Milcarek, Susan Coakley, Suzanne Walker, Beth Eaby-Sandy and Alexandre Hageboutros Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer Cancer 118

Version of Record online: 27 APR 2012 | DOI: 10.1002/cncr.27576

Maintenance bevacizumab alone after front-line bevacizumab, pemetrexed, and carboplatin in patients with advanced, nonsquamous nonsmall cell lung cancer produces a median survival of 17.1 months. The treatment regimen is well tolerated overall.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH